News
Examining the Efficacy of Toceranib Phosphate (Palladia) as a Primary and/or Adjuvant Agent in the Treatment of Feline Oral Squamous Cell Carcinoma |
12/28/2011
This is a non-randomized study to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.
This is a non-randomized study to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.
Examining the Efficacy of Toceranib Phosphate (Palladia) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal Carcinoma |
12/28/2011
Non-randomized study examining the efficacy of toceranib alone or radiation therapy plus toceranib. The financial incentive includes toceranib and follow-up rechecks depending on the study arm the patient is in.
Non-randomized study examining the efficacy of toceranib alone or radiation therapy plus toceranib. The financial incentive includes toceranib and follow-up rechecks depending on the study arm the patient is in.
Partially funded clinical trial for dogs with solid tumors |
08/08/2011
Trial Summary A total of 15 dogs with spontaneous tumors are expected to be enrolled into this clinical trial. Dogs will receive a single dose of the Test Article over 1 hr, for two consecutive days. Dogs will need to remain in the hospital for the first 48 hours of the study for blood samples and toxicity evaluation. Dogs will be evaluated on Day 8 of the study at which time the study will end.
Trial Summary A total of 15 dogs with spontaneous tumors are expected to be enrolled into this clinical trial. Dogs will receive a single dose of the Test Article over 1 hr, for two consecutive days. Dogs will need to remain in the hospital for the first 48 hours of the study for blood samples and toxicity evaluation. Dogs will be evaluated on Day 8 of the study at which time the study will end.
Funded Clinical Trial for Dogs with melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma. |
08/08/2011
Trial Summary A minimum of 100 dogs with solid tumors will be treated with modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required at 2,4,7, and 14 days. While the patient remains on study, there will also be rechecks at 1 and 2 months from the initial treatment.
Trial Summary A minimum of 100 dogs with solid tumors will be treated with modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required at 2,4,7, and 14 days. While the patient remains on study, there will also be rechecks at 1 and 2 months from the initial treatment.
Clinical Trial for Dogs with Osteosarcoma |
03/29/2011
NEVOG is currently participating in a clinical trial for canine osteosarcoma. Dogs enrolled in this study will receive carboplatin chemotherapy and then will be randomized to receive either Palladia/piroxicam/cyclophosphamide or piroxicam/cyclophosphamide alone. Patients must return every 3 weeks during the chemotherapy phase of the trial. Once the second phase of the trial is started, patients must return at Days 14 and 28 then every 28 days thereafter. This study is partially funded. Patients enrolled on the study will receive free carboplatin, free Palladia if randomized to receive this drug and a financial incentive for the rechecks.
NEVOG is currently participating in a clinical trial for canine osteosarcoma. Dogs enrolled in this study will receive carboplatin chemotherapy and then will be randomized to receive either Palladia/piroxicam/cyclophosphamide or piroxicam/cyclophosphamide alone. Patients must return every 3 weeks during the chemotherapy phase of the trial. Once the second phase of the trial is started, patients must return at Days 14 and 28 then every 28 days thereafter. This study is partially funded. Patients enrolled on the study will receive free carboplatin, free Palladia if randomized to receive this drug and a financial incentive for the rechecks.
N.E.V.O.G. is now seeing patients in Cape Cod MA, Manchester NH and Newington, NH. |
03/29/2011
The New England Veterinary Oncology Group LLP (NEVOG) the only private, comprehensive, veterinary oncology care center in New England based in Waltham MA, is now seeing patients in New Hampshire at the Southern New Hampshire Veterinary Referral Hospital in Manchester, NH and the Veterinary Emergency, Critical Care and Cancer Center of NH in Newington as well as Cape Cod at Cape Cod Veterinary Specialists. Drs. Andy Abbo, Kim Cronin, Erin Romansik, Kari Rosen, Michelle Silver and Sheri Siegel bring to the Cape Cod, Manchester and Newington offices the same high quality and compassionate care for which NEVOG is known.
The New England Veterinary Oncology Group LLP (NEVOG) the only private, comprehensive, veterinary oncology care center in New England based in Waltham MA, is now seeing patients in New Hampshire at the Southern New Hampshire Veterinary Referral Hospital in Manchester, NH and the Veterinary Emergency, Critical Care and Cancer Center of NH in Newington as well as Cape Cod at Cape Cod Veterinary Specialists. Drs. Andy Abbo, Kim Cronin, Erin Romansik, Kari Rosen, Michelle Silver and Sheri Siegel bring to the Cape Cod, Manchester and Newington offices the same high quality and compassionate care for which NEVOG is known.
2011 Office Hour Changes |
01/03/2011
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them on our web site.
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them on our web site.
Palladia, the new drug from Pfizer. |
07/22/2009
There has been much buzz and excitement surrounding FDA approval of Palladia (Pfizer), which is new drug licensed for treatment of mast cell tumors in dogs. Palladia is in the family of drugs called tyrosine kinase inhibitors which have been used in the treatment of cancer in humans for many years. Not only does Palladia provide veterinarians with a novel way to treat some of the more difficult mast cell tumors, it represents a commitment from drug companies like Pfizer to developing therapies specific for our veterinary cancer patients. Palladia is currently available only through veterinary oncologists and other selected specialists.
There has been much buzz and excitement surrounding FDA approval of Palladia (Pfizer), which is new drug licensed for treatment of mast cell tumors in dogs. Palladia is in the family of drugs called tyrosine kinase inhibitors which have been used in the treatment of cancer in humans for many years. Not only does Palladia provide veterinarians with a novel way to treat some of the more difficult mast cell tumors, it represents a commitment from drug companies like Pfizer to developing therapies specific for our veterinary cancer patients. Palladia is currently available only through veterinary oncologists and other selected specialists.
Emergency on call for active patients |
08/21/2008
NEVOG is pleased to offer an on-call after hours emergency service. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
NEVOG is pleased to offer an on-call after hours emergency service. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
Pet Friendly Hotels |
11/23/2007
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
781 684 8777
781 684 8688
Dr. Sheri Siegel